Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Genetics

Topic: Amyloid, tau and blood-test diagnosis

RBC DHA was associated with a positive (improved) global cognition (PACC) rate of change (estimate: 0.011; 95% CI: 0.001, 0.021; P = 0.024). No statistically significant interactions were observed for sex, APOE-ε4 carriership, or AD pathology. Higher RBC ALA status was associated with positive rate of change (better performing) in visual processing (estimate: 0.425; 95% CI: 0.168, 0.682; P = 0.001). In individuals at risk of AD, RBC DHA and RBC ALA show positive associations with longitudinal cognition. These findings add to the observational evidence linking ω-3 FAs with improved brain health. This trial was registered at clinicaltrials.gov as NCT02485730 (https://clinicaltrials.gov/study/NCT02485730).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lázaro, I., Brugulat‐Serrat, A., Suárez‐Calvet, M., Fauria, K., Minguillón, C., Gispert, J. D., et al. (2025). Red blood cell ω-3 status and longitudinal cognition in individuals at risk of Alzheimer disease. Journal of Nutrition. https://doi.org/10.1016/j.tjnut.2025.09.032

Vancouver

Lázaro I, Brugulat‐Serrat A, Suárez‐Calvet M, Fauria K, Minguillón C, Gispert JD, et al. Red blood cell ω-3 status and longitudinal cognition in individuals at risk of Alzheimer disease. Journal of Nutrition. 2025. doi:10.1016/j.tjnut.2025.09.032. PMID: 41022152.

BibTeX

@article{lazaro2025-41022152,
  author  = {Lázaro, Iolanda and Brugulat‐Serrat, Anna and Suárez‐Calvet, Marc and Fauria, Karine and Minguillón, Carolina and Gispert, Juan Domingo and Molinuevo, José Luís and Harris, William S. and others},
  title   = {{Red blood cell ω-3 status and longitudinal cognition in individuals at risk of Alzheimer disease}},
  journal = {Journal of Nutrition},
  year    = {2025},
  doi     = {10.1016/j.tjnut.2025.09.032},
  pmid    = {41022152},
  url     = {https://doi.org/10.1016/j.tjnut.2025.09.032}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In individuals at risk of Alzheimer disease, higher red blood cell DHA was associated with improved global cognition rate of change and higher ALA with better visual processing, with no significant interactions for sex, APOE-ε4 carriership, or AD pathology. These are observational associations, and the authors say they add to observational evidence linking ω-3 fatty acids with brain health.

Study details

How this study scored 51/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 49 of the 96 points it could be judged on, which is 51 of 100. Total 51 of 100.49 of the 96 points we could judge = 51 of 100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 49 of the 96 points we could judge it on, which is 51 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Nutrition)
Journal's citation record 3 / 4 Journal of Nutrition: journal h-index 372 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 323 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.7 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 0 / 3 Instituto de Salud Carlos III: institution h-index 649 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 9 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41022152)
Free to read 2 / 2 Free to read
Points 49 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 49 of the 96 points we could judge it on is 51 out of 100.
Total 51 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Genetics

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Genetics

See all studies in Genetics →